The vacuolar anti- Pseudomonal activity of neutrophil primary granule peptidyl-arginine deiminase enzymes

Front Immunol. 2024 Oct 18:15:1452393. doi: 10.3389/fimmu.2024.1452393. eCollection 2024.

Abstract

The role of neutrophils in host defense involves several cell processes including phagocytosis, degranulation of antimicrobial proteins, and the release of neutrophil extracellular traps (NETs). In turn, dysregulated cell activity is associated with the pathogenesis of airway and rheumatic diseases, in which neutrophil-derived enzymes including peptidyl-arginine deiminases (PADs) play a role. Known physiological functions of PADs in neutrophils are limited to the activity of PAD isotype 4 in histone citrullination in NET formation. The aim of this study was to extend our knowledge on the role of PADs in neutrophils and, specifically, bacterial killing within the confines of the phagocytic vacuole. Human neutrophils were fractionated by sucrose gradient ultracentrifuge and PADs localized in subcellular compartments by Western blot analysis. Direct interaction of PADs with Pseudomonas aeruginosa (P. aeruginosa) was assessed by flow cytometry and Western blot overlay. The participation of neutrophil PAD2 and PAD4 in killing of P. aeruginosa was assessed by inclusion of PAD-specific inhibitors. In vitro, bactericidal activity of recombinant human PAD2 or PAD4 enzymes against P. aeruginosa was determined by enumeration of colony-forming units (CFU). Together with neutrophil elastase (NE), PAD2 and PAD4 were localized to primary granules and, following activation with particulate stimuli, were degranulated in to the phagocytic vacuole. In vitro, PAD2 and PAD4 bound P. aeruginosa (p = 0.04) and significantly reduced bacterial survival to 49.1 ± 17.0 (p < 0.0001) and 48.5 ± 13.9% (p < 0.0001), respectively. Higher antibacterial activity was observed at neutral pH levels with the maximum toxicity at pH 6.5 and pH 7.5, comparable to the effects of neutrophil bactericidal permeability increasing protein. In phagosomal killing assays, inclusion of the PAD2 inhibitor, AFM-30a, or PAD4 inhibitor, GSK484, significantly increased survival of P. aeruginosa (AFM-30a, p = 0.05; and GSK484, p = 0.0079). Results indicate that PAD2 and PAD4 possess antimicrobial activity and are directly involved in the neutrophil antimicrobial processes. This study supports further research into the development of PAD-based antimicrobials.

Keywords: antimicrobial activity; bactericidal permeability increasing protein; neutrophils; peptidyl-arginine deiminases; phagocytic vacuole; primary granules.

MeSH terms

  • Extracellular Traps / immunology
  • Extracellular Traps / metabolism
  • Humans
  • Neutrophils* / immunology
  • Phagocytosis
  • Protein-Arginine Deiminase Type 2
  • Protein-Arginine Deiminase Type 4* / metabolism
  • Protein-Arginine Deiminases / metabolism
  • Pseudomonas Infections / immunology
  • Pseudomonas aeruginosa*
  • Vacuoles / metabolism

Substances

  • Protein-Arginine Deiminase Type 4
  • Protein-Arginine Deiminase Type 2
  • PADI2 protein, human
  • Protein-Arginine Deiminases
  • PADI4 protein, human

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from the Irish Research Council (Grant # GOIPG/2023/3100) and research Fellowship funding from Pfizer Healthcare Ireland (2021). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.